Orient Pharma Co., Ltd. (TPEX:4166)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
30.10
-0.05 (-0.17%)
Apr 30, 2025, 2:56 PM CST
33.19%
Market Cap 6.72B
Revenue (ttm) 1.22B
Net Income (ttm) 107.37M
Shares Out 223.04M
EPS (ttm) 0.48
PE Ratio 62.63
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 30,837
Average Volume 99,887
Open 30.85
Previous Close 30.15
Day's Range 29.95 - 30.90
52-Week Range 24.15 - 50.70
Beta -0.08
RSI 43.42
Earnings Date Apr 22, 2025

About Orient Pharma

Orient Pharma Co., Ltd. engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson’s and Alzheimer’s diseases; and products for the treatment of sialorrhea, tuberculosis, and attention deficit hyperactivity disorder. It is also developing drug delivery technologies, such as multi-stages-controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and ... [Read more]

Sector Healthcare
Founded 2008
Employees 173
Stock Exchange Taipei Exchange
Ticker Symbol 4166
Full Company Profile

Financial Performance

In 2024, Orient Pharma's revenue was 1.22 billion, an increase of 37.41% compared to the previous year's 889.91 million. Earnings were 107.37 million, an increase of 381.76%.

Financial Statements

News

There is no news available yet.